Signalisation PI3K/Akt/mTOR
Les inhibiteurs de la signalisation PI3K/Akt/mTOR sont des composés qui ciblent les voies de la phosphoinositide 3-kinase (PI3K), de la kinase Akt et de la cible de la rapamycine chez les mammifères (mTOR). Ces voies sont des régulateurs critiques de la croissance cellulaire, de la survie, du métabolisme et de l'autophagie, ce qui en fait des cibles clés dans la recherche sur le cancer et les troubles métaboliques. Inhiber ces voies peut aider à contrôler la croissance et la prolifération tumorales, offrant ainsi des stratégies thérapeutiques potentielles pour divers cancers et autres maladies caractérisées par une signalisation cellulaire dysrégulée. Chez CymitQuimica, nous offrons une sélection complète d'inhibiteurs de haute qualité de PI3K/Akt/mTOR pour soutenir vos recherches en oncologie, signalisation cellulaire et maladies métaboliques.
Sous-catégories appartenant à la catégorie "Signalisation PI3K/Akt/mTOR"
- AMPK(158 produits)
- ATM/ATR(71 produits)
- ADN-PK(51 produits)
- EGFR(572 produits)
- MELK(7 produits)
- PDK(9 produits)
- PI3K(242 produits)
- S6 Kinase(9 produits)
- gsk-3(112 produits)
- mTOR(144 produits)
Affichez 2 plus de sous-catégories
1038 produits trouvés pour "Signalisation PI3K/Akt/mTOR"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
HER2-IN-12
<p>HER2-IN-12 is an HER2 inhibitor with an IC50 value of 121 nM and can be used to study cancers such as breast cancer.</p>Formule :C17H18BrN5O2SCouleur et forme :SolidMasse moléculaire :436.33Neptinib
CAS :<p>Neptinib (NEP010), a derivative of Afatinib, exhibits enhanced antitumor properties and improved pharmacokinetics when administered orally. It demonstrates a notable suppression of tumor expansion in mouse models of non-small cell lung cancer harboring various EGFR mutations. Furthermore, Neptinib effectively inhibits the EGFR kinase family, exhibiting IC 50 values of 0.24 nM for EGFR wt, 7.25 nM for EGFR L858R/T790M, 0.46 nM for EGFR L858R, and 1.79 nM for EGFR T790M.</p>Formule :C22H23ClFN5O2Couleur et forme :SolidMasse moléculaire :443.90PI4KIII β inhibitor 5
CAS :<p>PI4KIII beta inhibitor 5 (Compound 43) is an inhibitor of PI4KIIIβ with an IC50 of 19 nM. By inhibiting the PI3K/AKT pathway, it induces apoptosis in cancer cells, causes cell cycle arrest at the G2/M phase, and promotes autophagy. Additionally, PI4KIII beta inhibitor 5 demonstrates significant anti-tumor activity in the H446 small cell lung cancer xenograft model. This compound is applicable in cancer research studies.</p>Formule :C24H27F2N3O4S2Couleur et forme :SolidMasse moléculaire :523.616JBJ-02-112-05
CAS :<p>JBJ-02-112-05 is a potent, mutant-selective, allosteric and orally active inhibitor of EGFR with an IC 50 of 15 nM for EGFR L858R/T790M [1].</p>Formule :C27H20N4O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :464.54Lys(CO-C3-p-I-Ph)-O-tBu
CAS :<p>Lys(CO-C3-p-I-Ph)-O-tBu, a pharmacokinetic modifier (PK modifier), enhances the pharmacokinetic properties of PSMA ligand molecules by increasing their residence time in plasma through improved binding to albumin and reducing absorption by the salivary glands, potentially extending the active compound's half-life. Moreover, Ac-PSMA-trillium is an effective PSMA-targeting compound for various biological applications when modified with different radioactive isotopes. When labeled with 111 In, it serves as a DOTA chelating agent and imaging agent. Alternatively, when labeled with 225 Ac, it acts as a Macropa chelator for targeted radionuclide therapy (TRT) in researching metastatic castration-resistant prostate cancer (mCRPC) [1] [2].</p>Formule :C20H31IN2O3Couleur et forme :SolidMasse moléculaire :474.38EG31
CAS :<p>EG31 is an EGFR inhibitor that effectively suppresses the proliferation of triple-negative breast cancer (TNBC) cells by inhibiting the EGFR signaling pathway. It demonstrates a GI50 value of 498.90 nM for MDA-MB-231 cells and 740.73 nM for Hs578T cells, while also inducing apoptosis. Additionally, EG31 retains its antiproliferative activity against 5-fluorouracil (5-FU) resistant TNBC cells, with a GI50 of 519.5 nM. EG31 is applicable in research on TNBC resistance.</p>Formule :C30H13Br2N3O6Couleur et forme :SolidMasse moléculaire :671.25EGFR/HER2-IN-7
<p>EGFR/HER2-IN-7: Potent, selective dual inhibitor for MCF-7 cancer; IC50: EGFR 0.18μM, HER2 0.146μM, DHFR 0.907μM.</p>Formule :C19H21N3O2SCouleur et forme :SolidMasse moléculaire :355.45SIK2/3-IN-1
CAS :<p>SIK2/3-IN-1 (Compound 7S) is an orally active and selective inhibitor of SIK2/3. It significantly inhibits tumor growth without causing weight loss in the MV4-11 AML mouse CDX model. SIK2/3-IN-1 is applicable for research in MEF2C-dependent acute myeloid leukemia.</p>Formule :C20H19F3N6O2Couleur et forme :SolidMasse moléculaire :432.399EGFR-IN-17
<p>EGFR-IN-17: potent, selective EGFR inhibitor, IC50 of 0.2 nM, overcomes C797S drug resistance.</p>Formule :C27H31ClN7O3PCouleur et forme :SolidMasse moléculaire :568.01PIKfyve-IN-1
<p>PIKfyve-IN-1: potent, cell-active inhibitor for PIKfyve research, IC50=6.9 nM.</p>Formule :C20H21N5Couleur et forme :SolidMasse moléculaire :331.41EGFR-IN-38
CAS :<p>EGFR-IN-38: low-toxic acrylamide-derived EGFR inhibitor, targets NSCLC, patented for research on EGFR mutation-related diseases.</p>Formule :C25H24ClN7O2Couleur et forme :SolidMasse moléculaire :489.96LSD1/EGFR-IN-1
CAS :<p>LSD1/EGFR-IN-1 (compound L-1) is an effective inhibitor of LSD1, EGFRT790M/L858R, and EGFRL858R/T790M/C797S, with IC50 values of 6.24, 2.06, and 5.01 μM, respectively. This compound plays a significant role in cancer research.</p>Formule :C21H20ClN3O4Couleur et forme :SolidMasse moléculaire :413.854JBJ-09-063
CAS :<p>JBJ-09-063: EGFR inhibitor, IC50s 0.147-0.396 nM for various mutants; hinders EGFR/Akt/ERK1/2 phosphorylation; targets TKI-sensitive/resistant lung cancer.</p>Formule :C31H29FN4O3SCouleur et forme :SolidMasse moléculaire :556.65PI3K-IN-23
<p>PI3K-IN-23 is a (E)-9-oxooctadec-10-en-12-ynoic acid analogue that promotes glucose uptake (EC50: 7.00 μM).</p>Formule :C24H33NO4SCouleur et forme :SolidMasse moléculaire :431.59Sacibertinib
CAS :<p>Sacibertinib inhibits Trk, targeting EGFR-TK (EC50 110 nM) & HER2 (EC50 244 nM), with anticancer properties.</p>Formule :C32H31ClN6O4Couleur et forme :SolidMasse moléculaire :599.08Vulolisib
CAS :<p>Vulolisib inhibits PI3K (α: IC50 0.2nM, β: 168nM, γ: 90nM, δ: 49nM), taken orally with anti-cancer properties.</p>Formule :C18H19F2N5O3SCouleur et forme :SolidMasse moléculaire :423.44HER2-IN-6
CAS :<p>HER2-IN-6, a potent HER2 inhibitor, may target wild/mutant EGFR and HER2-mediated tumors. (Patent WO2021164697A1, compound 11)</p>Formule :C26H32N8O3Couleur et forme :SolidMasse moléculaire :504.58Aldometanib
CAS :<p>Aldometanib (LXY-05-029) is an oral aldolase inhibitor that maintains metabolic balance by blocking FBP and activating lysosomal AMPK.</p>Formule :C27H43Cl2IN2Degré de pureté :99.32% - 99.55%Couleur et forme :SolidMasse moléculaire :593.46AZD 3147
CAS :<p>AZD 3147 inhibits mTORC1 (40.7 nM), mTORC2 (5.75 nM), and PI3Kα/β/δ/γ (912/5495/9333/6310 nM IC50s).</p>Formule :C24H31N5O4S2Degré de pureté :99.99%Couleur et forme :SolidMasse moléculaire :517.66BAY-8400
<p>BAY-8400 is an orally active, potent and selective DNA-dependent protein kinase ( DNA-PK ) inhibitor ( IC 50 =81 nM) which shows synergistic efficacy in</p>Formule :C21H17F2N5ODegré de pureté :99.53%Couleur et forme :SolidMasse moléculaire :393.39EGFR-IN-7
CAS :<p>EGFR-IN-7 (TQB3804) is a selective and potent EGFR kinase inhibitor.</p>Formule :C32H41BrN9O2PDegré de pureté :95.32% - 99.64%Couleur et forme :SolidMasse moléculaire :694.6Sonolisib
CAS :<p>Sonolisib is an irreversible and pan-isoform inhibitor of PI3K (IC50=0.1 nM (p110α), 1.0 nM (p120γ), 2.9 nM (p110δ)).</p>Formule :C29H35NO8Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :525.59TLC9995-0188
CAS :<p>Tyrosine-protein kinase ABL, IC50: 1500 nM</p>Formule :C16H15N5Couleur et forme :Yellow SolidMasse moléculaire :277.331HMBD-001
<p>HMBD-001 is a humanized IgG1 monoclonal antibody inhibitor that targets HER3. By inhibiting the dimerization of HER3, HMBD-001 suppresses the growth and proliferation of tumor cells. It holds potential for research in cancer treatments, specifically for pancreatic cancer and non-small cell lung cancer.</p>Couleur et forme :Odour LiquidmTORC1-IN-1
<p>mTORC1-IN-1 (T1), a rapamycin homologue (rapalog) and selective inhibitor of mTORC1, controls cell growth and metabolism, with implications in various diseases</p>Degré de pureté :98%Couleur et forme :Odour SolidNimotuzumab (powder)
CAS :<p>Nimotuzumab (powder) is a humanized IgG1 monoclonal antibody that specifically targets the epidermal growth factor receptor (EGFR), possessing a dissociation constant (KD) of 0.21 nM. It blocks the binding to its ligand by targeting the extracellular domain of EGFR. Nimotuzumab exhibits strong antitumor activity by inducing both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), exerting cytolytic effects on target tumors.</p>Couleur et forme :LiquidAZD8154
CAS :<p>AZD8154 is a newly developed inhaled compound that selectively inhibits dual PI3Kγδ, aimed at treating airway inflammatory diseases.</p>Formule :C27H29N5O4S2Couleur et forme :SolidMasse moléculaire :551.68AS-604850
<p>AS-604850: PI3Kγ inhibitor, ATP-competitive, IC50=2.5μM, 30x> PI3Kδ/β, 18x> PI3Kα.</p>Formule :C11H5F2NO4SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :285.22PDK1-IN-RS2
CAS :<p>PDK1-IN-RS2, a PIFtide mimic, selectively inhibits PDK1, blocking S6K1 activation (Kd: 9 μM).</p>Formule :C15H9ClN2O2S3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :380.89Duligotuzumab
CAS :<p>Duligotuzumab (MEHD-7945A) is a bispecific humanised IgG-κ monoclonal antibody targeting HER3 and EGFR, solid tumours, head and neck cancer,colorectal cancer.</p>Degré de pureté :95%Couleur et forme :LiquidBisindolylmaleimide I HCl
CAS :<p>Bisindolylmaleimide I HCl is a specific ATP-competitive PKC inhibitor.</p>Formule :C25H25ClN4O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :448.95EGFR-IN-82
CAS :<p>EGFR-IN-82 (Compound 8a) is a potent, orally active inhibitor of EGFR, exhibiting IC50 values of 0.09 nM for EGFR L858R/T790M/C797S and 0.06 nM for EGFR Del19/</p>Formule :C32H41BrN9O2PDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :694.6Duvelisib (R enantiomer)
CAS :<p>Duvelisib R enantiomer (IPI-145 R enantiomer) is an enantiomer of Duvelisib with lower activity. Duvelisib is a PI3K inhibitor.</p>Formule :C22H17ClN6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :416.86PI3Kδ-IN-13
CAS :<p>PI3Kδ-IN-13 (compound 89), with an IC50 value of 2.6 nM, is an inhibitor of PI3Kδ, applicable for researching diseases involving cell proliferation, including</p>Formule :C27H39N7O4S2Couleur et forme :SolidMasse moléculaire :589.77MDVN1003
CAS :<p>MDVN1003 inhibits BTK & PI3Kδ in B cells, blocking NHL growth; it kills lymphoma cells, not erythroblasts.</p>Formule :C22H20FN7ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :417.44YK-029A
CAS :<p>YK-029A, an orally active EGFR mutant inhibitor, targets both EGFR T790M and EGFRex20ins mutations.</p>Formule :C27H32N8O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :500.6EGFR-IN-123
CAS :<p>EGFR-IN-123 (compound D06) is an effective EGFR inhibitor. It exhibits inhibitory activity against several cell lines including PC-9G, A549, A431, and HCT116, with IC50 values of 0.74, 1.36, 1.20, and 2.53 μM respectively.</p>Formule :C24H27F3N6OCouleur et forme :SolidMasse moléculaire :472.51EGFR-IN-122
CAS :<p>EGFR-IN-122 (compound Yfq07) serves as a potent inhibitor of EGFR. It effectively inhibits the proliferation of PC-9GR and HCC827GR cells.</p>Formule :C19H20N4O3Couleur et forme :SolidMasse moléculaire :352.39
